Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY)  and Novo Nordisk (NVO)  stock.As the major players in the hyper-scale shift of injectable drugs that treat obesity, investors may be pondering which pharmaceutical giant is the better investment at the moment.  Zepbound & Wegovy Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy are both once-weekly injectable medications designed for chronic weight management. Both have added billions ...